Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma

Authors

• Grace Baek, Fred Hutchinson Cancer Center
• Nancy L Bartlett, Washington University School of Medicine in St. Louis
• Marcus Watkins, Washington University School of Medicine in St. Louis
• et al.

Journal

Blood Advances

Publication Date

5-26-2026

Volume

10

Issue

10

First Page

3565

Last Page

3571

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2025018267

Rights and Permissions

Baek G, Varma G, Yamshon S, van Besien H, Bartlett NL, Watkins M, Shah HR, Baron K, Merryman RW, Falade AS, Svoboda J, Prischak S, D'Angelo C, Lukowski JD, Advani RH, Yeung AH, Rosenberg M, Voutsinas J, Di M, Lynch R, Poh C, Raghunathan V, Shadman M, Smith S, Till BG, Ujjani C, Diefenbach CS, Gopal AK. Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma. Blood Adv. 2026 May 26;10(10):3565-3571. doi: 10.1182/bloodadvances.2025018267. © 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Baek, Grace; Bartlett, Nancy L; Watkins, Marcus; and et al., "Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma." Blood Advances. 10, 10. 3565 - 3571. (2026).
https://digitalcommons.wustl.edu/oa_4/7316

Additional Links

Supplemental material is available for this article at publisher site.